12
Participants
Start Date
February 25, 2019
Primary Completion Date
December 17, 2020
Study Completion Date
May 28, 2024
MB-CART2019.1 Dose level 1
This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.
MB-CART2019.1 Dose level 2
This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.
Universitätsklinikum Hamburg-Eppendorf, Department of Stem Cell Transplantation, Hamburg
University Hospital Cologne - Department for Internal Medicine I, Cologne
Klinikum Augsburg, II. Med. Klinik Haematologie / Onkologie, Augsburg
Lead Sponsor
Collaborators (1)
ICON plc
INDUSTRY
Miltenyi Biomedicine GmbH
INDUSTRY